Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 0.62 |
| ▸ | S1PR3 | Q99500 | 16/20 | 0.62 |
| ▸ | S1PR2 | O95136 | 11/20 | 0.62 |
| ▸ | S1PR4 | O95977 | 11/20 | 0.62 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.57 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.54 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6130136 | 0.85 | S1PR1 (0.57) | S1PR1S1PR3S1PR2S1PR4ENPP2 | |
| SCHEMBL6130131 | 0.85 | S1PR4 (0.46) | S1PR1S1PR3S1PR2S1PR4ENPP2 | |
| SCHEMBL6130130 | 0.81 | S1PR1 (0.77) | S1PR1S1PR3S1PR2S1PR4ENPP2 | |
| SCHEMBL13421980 | 0.78 | ENPP2 (0.74) | S1PR1S1PR3S1PR2S1PR4ENPP2 | |
| SCHEMBL28441940 | 0.77 | PPARG (0.53) | S1PR1S1PR3S1PR2S1PR4 | |
| SCHEMBL17083799 | 0.76 | S1PR1 (1.00) | S1PR1S1PR3S1PR2S1PR4ENPP2 | |
| SCHEMBL6130113 | 0.76 | S1PR1 (1.00) | S1PR1S1PR3S1PR2S1PR4ENPP2 | |
| SCHEMBL14801617 | 0.76 | S1PR1 (1.00) | S1PR1S1PR3S1PR2S1PR4ENPP2 | |
| SCHEMBL10435795 | 0.75 | ALDH1A1 (0.60) | S1PR1S1PR3S1PR2S1PR4 | |
| SCHEMBL28164960 | 0.75 | HPGD (0.44) | S1PR1S1PR3S1PR2S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315735-A4 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1315735-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | Merck & Co., Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6437165-B1 | USEFUL FOR TREATING IMMUNE MEDIATED DISEASES AND CONDITIONS, SUCH AS BONE MARROW, ORGAN AND TISSUE TRANSPLANT REJECTION. | MERCK & CO., INC. | 2002-08-20 | — | — | US | disclosed |
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | MERCK & CO., INC. | 2002-07-11 | — | — | US | disclosed |
| WO-2002018395-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO., INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | ALPP, PPIP5K2, ALPI | S1PR1 382/4885S1PR3 520/4885S1PR2 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.